Group 1 - Medtronic's MiniMed Group has taken a significant step towards independent listing with plans to go public on the Nasdaq under the ticker "MMED" [1] - The IPO aims to issue 28 million shares priced between $25 and $28 each, potentially raising up to $784 million and valuing the business at approximately $7.86 billion [1] - Post-IPO, Medtronic is expected to retain about 90% ownership of MiniMed, which may decrease to around 89% if underwriters fully exercise their over-allotment option [1] Group 2 - This IPO marks a crucial milestone since Medtronic announced its strategic shift in May 2024, aiming to streamline its corporate structure by spinning off the diabetes division [2] - MiniMed has a long history as a leader in the insulin pump market, having been acquired by Medtronic in 2001 for approximately $3.3 billion [2] - Despite generating annual revenues of about $2.7 billion to $2.9 billion in fiscal year 2025, MiniMed is currently operating at a net loss [2]

Group 1 - Medtronic's MiniMed Group is taking a significant step towards independent listing with plans to go public on NASDAQ under the ticker "MMED" [1] - The IPO aims to issue 28 million shares priced between $25 and $28 each, potentially raising $784 million and valuing the business at approximately $7.86 billion [1] - Post-IPO, Medtronic is expected to retain about 90% ownership of MiniMed, which may decrease to around 89% if underwriters fully exercise their over-allotment option [1] Group 2 - This IPO marks a crucial milestone since Medtronic announced its strategic shift in May 2024, aiming to simplify its corporate structure by spinning off the diabetes division [2] - MiniMed has a historical presence in the insulin pump market since 1983 and was acquired by Medtronic for approximately $3.3 billion in 2001 [2] - Despite generating annual revenues of about $2.7 to $2.9 billion in fiscal year 2025, MiniMed is currently operating at a net loss [2]